Gorodetska, Ielizaveta
Lukiyanchuk, Vasyl
Gawin, Marta
Sliusar, Myroslava
Linge, Annett
Lohaus, Fabian
Hölscher, Tobias
Erdmann, Kati
Fuessel, Susanne
Borkowetz, Angelika
Wojakowska, Anna
Fochtman, Daniel
Reardon, Mark
Choudhury, Ananya
Antonelli, Yasmin
Leal-Egaña, Aldo
Köseer, Ayse Sedef
Kahya, Uğur
Püschel, Jakob
Petzold, Andrea
Klusa, Daria
Peitzsch, Claudia
Kronstein-Wiedemann, Romy
Tonn, Torsten
Marczak, Lukasz
Thomas, Christian
Widłak, Piotr
Pietrowska, Monika
Krause, Mechthild
Dubrovska, Anna
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SPP 2084: µBONE, #401326337, DFG SPP 2084: µBONE, #491716269)
Helmholtz-Zentrum Dresden - Rossendorf e.V.
Article History
Received: 25 July 2024
Accepted: 12 January 2025
First Online: 24 March 2025
Declarations
:
: Clinical specimens were collected with informed consent from all subjects. The ethical approvals for these retrospective analyses were granted by the local Ethics Committees and Institutional Review Boards of the Faculty of Medicine, Technische Universität Dresden, Germany (BO-EK-470122024 and BO-EK-350082024) and the University of Manchester, Manchester Cancer Research Centre (#15/NW/0559).
: All authors have agreed to publish this manuscript.
: In the past years, Dr. Mechthild Krause received funding for her research projects by IBA (2016), Merck KGaA (2014–2018 for preclinical study; 2018–2020 for clinical study), Medipan GmbH (2014–2018). In the past five years, Dr. Krause and Dr. Linge have been involved in a publicly funded (German Federal Ministry of Education and Research) project with the companies Medipan, Attomol GmbH, GA Generic Assays GmbH, Gesellschaft für medizinische und wissenschaftliche genetische Analysen, Lipotype GmbH and PolyAn GmbH (2019–2021). For the present manuscript, none of the above-mentioned funding sources were involved. All other authors declare that they have no competing interest.